DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Ambroxol is an investigational drug.
There have been 23 clinical trials for Ambroxol. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2007.
The most common disease conditions in clinical trials are Pharyngitis, Parkinson Disease, and Dementia. The leading clinical trial sponsors are Boehringer Ingelheim, Sanofi, and Hyundai Pharmaceutical Co., LTD.
Recent Clinical Trials for Ambroxol
|A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer||Institut du Cancer de Montpellier - Val d'Aurelle||Phase 3|
|Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia||Lawson Health Research Institute||Phase 1/Phase 2|
|A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respirator||Zambon SpA||Phase 3|